FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220883503> ?p ?o ?g. }

• W4220883503 endingPage "2881" @default.
• W4220883503 startingPage "2871" @default.
• W4220883503 abstract "Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm driven by the JAK2 V617F (or rarely exon 12) mutation. Its natural history can extend over a few decades, and therefore treatment planning is predicated on continual reassessment of traditional risk features (age, prior thrombosis) to evaluate the need for cytoreduction besides foundational therapy with low-dose aspirin and stringent phlebotomy. Shorter- and longer-term patient goals should be considered in light of several variables such as comorbid conditions (especially cardiovascular risk factors), disease symptoms, and the risk-benefit profile of available drugs. While hydroxyurea has been the pro forma choice of cytoreduction for many practitioners over the last half-century, the more recent regulatory approvals of ruxolitinib and ropeginterferon-alfa-2b, based on phase 3 randomized trials, highlight an expanding portfolio of active drugs. Obtaining high-level evidence for short-term clinical trial endpoints such as hematocrit control, symptom burden/quality of life, splenomegaly, and JAK2 V617F allele burden lies within the timeline of most studies. However, in many cases, it may not be possible to adequately power trials to capture significant differences in the typically low event rates of thrombosis as well as longer-horizon endpoints such as evolution to myelofibrosis and acute myeloid leukemia and survival. This Perspective highlights the challenges of addressing these data gaps and outstanding questions in the emerging treatment landscape of PV." @default.
• W4220883503 created "2022-04-03" @default.
• W4220883503 creator A5065621786 @default.
• W4220883503 date "2022-05-12" @default.
• W4220883503 modified "2023-09-30" @default.
• W4220883503 title "Treatment and clinical endpoints in polycythemia vera: seeking the best obtainable version of the truth" @default.
• W4220883503 cites W1935822737 @default.
• W4220883503 cites W1979832242 @default.
• W4220883503 cites W1980972742 @default.
• W4220883503 cites W1982267544 @default.
• W4220883503 cites W1991495650 @default.
• W4220883503 cites W1996502308 @default.
• W4220883503 cites W2015113479 @default.
• W4220883503 cites W2024770530 @default.
• W4220883503 cites W2040000334 @default.
• W4220883503 cites W2048488970 @default.
• W4220883503 cites W2051259791 @default.
• W4220883503 cites W2066465348 @default.
• W4220883503 cites W2067829130 @default.
• W4220883503 cites W2068493370 @default.
• W4220883503 cites W2069651950 @default.
• W4220883503 cites W2070959673 @default.
• W4220883503 cites W2072881492 @default.
• W4220883503 cites W2077980460 @default.
• W4220883503 cites W2086511628 @default.
• W4220883503 cites W2094200744 @default.
• W4220883503 cites W2094456737 @default.
• W4220883503 cites W2097692898 @default.
• W4220883503 cites W2100089051 @default.
• W4220883503 cites W2112316414 @default.
• W4220883503 cites W2115351357 @default.
• W4220883503 cites W2119941797 @default.
• W4220883503 cites W2121743767 @default.
• W4220883503 cites W2122395736 @default.
• W4220883503 cites W2123587611 @default.
• W4220883503 cites W2127237644 @default.
• W4220883503 cites W2141249732 @default.
• W4220883503 cites W2142506642 @default.
• W4220883503 cites W2147370660 @default.
• W4220883503 cites W2147666686 @default.
• W4220883503 cites W2153170459 @default.
• W4220883503 cites W2158669800 @default.
• W4220883503 cites W2168134980 @default.
• W4220883503 cites W2178961707 @default.
• W4220883503 cites W2320032845 @default.
• W4220883503 cites W2339708061 @default.
• W4220883503 cites W2528188718 @default.
• W4220883503 cites W2529479111 @default.
• W4220883503 cites W2533901897 @default.
• W4220883503 cites W2549398235 @default.
• W4220883503 cites W2556415172 @default.
• W4220883503 cites W2557590973 @default.
• W4220883503 cites W2559562829 @default.
• W4220883503 cites W2614282478 @default.
• W4220883503 cites W2735582214 @default.
• W4220883503 cites W2744846745 @default.
• W4220883503 cites W2783991821 @default.
• W4220883503 cites W2790003237 @default.
• W4220883503 cites W2806455593 @default.
• W4220883503 cites W2884400240 @default.
• W4220883503 cites W2888433312 @default.
• W4220883503 cites W2947677238 @default.
• W4220883503 cites W2948738889 @default.
• W4220883503 cites W2948784783 @default.
• W4220883503 cites W2972422263 @default.
• W4220883503 cites W2986723506 @default.
• W4220883503 cites W2987869677 @default.
• W4220883503 cites W2999262601 @default.
• W4220883503 cites W3001373379 @default.
• W4220883503 cites W3003423609 @default.
• W4220883503 cites W3008905509 @default.
• W4220883503 cites W3013846794 @default.
• W4220883503 cites W3082046116 @default.
• W4220883503 cites W3088297778 @default.
• W4220883503 cites W3094678114 @default.
• W4220883503 cites W3096269688 @default.
• W4220883503 cites W3124458352 @default.
• W4220883503 cites W3133520808 @default.
• W4220883503 cites W3134567435 @default.
• W4220883503 cites W3134947063 @default.
• W4220883503 cites W3135642748 @default.
• W4220883503 cites W3165639147 @default.
• W4220883503 cites W3195336015 @default.
• W4220883503 cites W3204791941 @default.
• W4220883503 cites W3206984067 @default.
• W4220883503 cites W3211435658 @default.
• W4220883503 cites W3211437309 @default.
• W4220883503 cites W3213286283 @default.
• W4220883503 cites W3213561880 @default.
• W4220883503 cites W3213711010 @default.
• W4220883503 cites W3214588833 @default.
• W4220883503 cites W4200416144 @default.
• W4220883503 cites W4207057286 @default.
• W4220883503 cites W4225796302 @default.
• W4220883503 cites W942930643 @default.
• W4220883503 doi "https://doi.org/10.1182/blood.2022015680" @default.
• W4220883503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35271702" @default.
• W4220883503 hasPublicationYear "2022" @default.

• next